


Critical Care - Infection Diseases Network

2022 Inaugural Virtual Symposium

Life-Threatening Infections and COVID-19 Disease



ABOUT

This academic program was developed by the members of the Critical Care – Infectious Diseases Network, a group of clinicians and researchers trained in critical care medicine and infectious diseases/microbiology. This program is designed for specialists in internal medicine or surgery with an interest in severe and life-threatening infections and infections occurring in the critically ill. Critical care physicians, hospitalists and infectious diseases physicians in particular will find the material covered important in improving their clinical practice. Key topics to be discussed include optimization of antimicrobial therapy, newly introduced antimicrobials, resistance trends and, of course, the latest in COVID-19 data.

Learning Objectives

At the end of the conference, participants will be able to:

- understand advanced concepts in COVID diagnostics and therapeutics;
- appreciate how to optimize dosing to take advantage of PK principles in management of life-threatening infections;
- recognize the role of adjunctive and novel diagnostic techniques for serious infections;
- evaluate the relative importance of antimicrobial resistance with respect to therapy.

Please Note

- All times listed in the program are in Eastern Time.
- A minimum of 25% of each session will be dedicated to participant interaction.



Thursday, February 24, 2022				
8:55 a.m. EST		Delegates – Virtual Check-In		
9:00 a.m		Opening Address		
9:15 a.m.	LINE 1	Anand Kumar and CCIDN Organizing Committee with special address by Dennis Maki and		
		Bruce Light		
Concurrent Sess	ions: Block	1		
9:20 a.m 9:55 a.m.	LINE 1	What's New in Antimicrobials Used in the ICU?		
		Wendy Sligl		
	LINE 2	Antimicrobial Stewardship in the Face of Suspected Sepsis		
	LIIVL Z	Sameer Kadri		
Concurrent Sess	ions: Block			
10:00 a.m	LINE 1	What's New in Antimicrobial Resistance in the ICU?		
10:35 a.m.	LIIVE I	Andre Kalil		
	LINE 2	The Modern Approach to the Diagnosis of Fungal Sepsis		
	LIIVL Z	Coleman Rotstein		
10:35 a.m 10):45 a.m.	Break		
Concurrent Sess	ions: Block	3		
10:45 a.m	LINE 1	Options for Difficult-To-Treat Gram-Negative Infections – What to Choose and When		
11:20 a.m.	2	Matteo Bassetti		
	LINE 2	Treating Invasive Candida Sepsis		
		Eric Bow		
Concurrent Sess	ions: Block			
11:25 a.m. –	LINE 1	Considerations for the Treatment of HAP/VAP in Patients at High Risk of Mortality		
12:00 p.m.	LIIVL I	Ignacio Martin-Loeches		
	LINE 2	Options for MRSA Infections – What to Choose and When		
	LIIVE Z	Salman Qureshi		
12:00 a.m 12	2:30 p.m.	Lunch		
Concurrent Sess	ions: Block	5		
12:30 p.m	LINE 1	Vancomycin AUC for Serious MSRA Infections		
1:05 p.m.	LIINE I	Tom Lodise		
	LINE 2	Initiating, Escalating, De-escalating and Stopping Antibiotics in the ICU Patient		
		Nick Daneman		
Concurrent Sess	ions: Block			
1:10 p.m	LINE 1	CAP Empiric Therapy and De-escalation Strategies		
1:45 p.m.		Srinivas Murthy		
	LINE 2	Use of Immunoglobulin Therapy for Infection/Sepsis in the ICU		
	LINE Z	Evangelos Giamarellos-Bourboulis		
Concurrent Sess	ions: Block	7		
1:50 p.m	LINE 1	HAP Empiric Therapy and De-escalation Strategies		
2:25 p.m.		Andre Kalil		
	LINE 2	New Perspectives on Severe Influenza and Non-influenza Respiratory Virus Infections		
		Nelson Lee		

2:25 p.m 2:35 p.m.		Break			
Concurrent Sessions: Block 8					
2:35 p.m	LINE 1	Prolonged and Extended β-lactam Infusion for Critical Infections in ICU			
3:10 p.m.	LIINE 1	Jason Roberts			
	LINE 2	How to Use Procalcitonin in the ICU			
		Gloria Vazquez-Grande			
Concurrent Sessions: Block 9					
3:15 p.m. –	LINE 1	Therapeutic Drug Monitoring in the ICU			
3:50 p.m.	LIIVL I	Jason Roberts			
	LINE 2	Clinical Management Guidelines for Pandemics: Are They Worth the Effort?			
	LIIVL Z	Henry Masur			
Concurrent Sessions: Block 10					
3:55 p.m. –	LINE 1	Emerging Rapid Microbiologic Molecular Diagnostic Technologies			
4:30 p.m.	LINE 1	Donna Wolk and Shravan Kethireddy			
	LINE 2	Antimicrobials In Critical Illness: How Fast Is Fast Enough?			
	LIIVL Z	Mike Klompas			
Concurrent Sessions: Block 11					
4:35 p.m	LINE 1	Antimicrobials in Sepsis and Septic Shock: How Fast is Too Fast?			
5:10 p.m.	LINE 1	Chris Seymour			
	LINE 2	Primer on Coronavirus Infections in Humans			
		Sylvain Lother			

Friday, February 25, 2022				
8:20 a.m. – 8:25 a.m.	Delegates – Virtual Check-In			
EST				
8:25 a.m. – 8:30 a.m.	Welcome			
	Anand Kumar			
8:30 a.m. – 9:10 a.m.	SARS			
	Robert Fowler			
	MERS			
	Yaseen Arabi			
9:10 a.m 9:40 a.m.	Through a Glass Darkly: Measuring Prognosis in COVID-19			
	Ryan Maves			
9:40 a.m 10:10 a.m.	COVID-19: The Pediatric Perspective			
	Angela Bates			
10:10 a.m 10:40 a.m.	Co-infections and Complications			
	Josh Douglas			
10:40 a.m 11:00 a.m.	Break			
11:00 a.m 11:30 a.m.	COVID-19 Vaccine Efficacy and Disease Severity among Immunocompromised Patients			
	Kelly MacDonald			
11:30 a.m 12:00 p.m.	Respiratory Injury and Mechanical Support			
	Salman Qureshi			

12:00 p.m1:00 p.m.	Lunch
1:00 p.m 1:30 p.m.	The Nature of Extra-Pulmonary Organ Injury and Support
	Ken Wood
1:30 p.m 2:00 p.m.	What We Know About Genetic, Clinical and Racial Predisposition
	Ken Baillie
2:00 p.m 2:30 p.m.	Heparin Therapy of COVID-19Theory and Data
	Ryan Zarychanski
2:30 p.m 2:45 p.m.	Break
2:45 p.m 3:15p.m.	Inpatient Passive Immune Therapy for COVID-19
	John Beigel
3:15 p.m 3:45 p.m.	Immune Modulation Therapy of Severe COVID-19
	Srinivas Murthy
3:45 p.m 4:15 p.m.	Inpatient Antiviral Therapy for COVID-19
	John Beigel
4:15 p.m. – 4:55 p.m.	COVID-19: Where We've Been and Where We're Going
	Amesh Adalja
4:55 p.m. – 5:00 p.m.	Closing Remarks

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the CPD Medicine Program, University of Manitoba for a maximum of 13.5 hours.

Participants should only claim credit for the actual number of hours attended.

The University of Manitoba CPD Medicine Program is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME).

AMA PRA Category 1 Credit™

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. More information on the process to convert Royal College MOC credit to AMA credit.

Read more on the Royal College agreement with the American Medical Association.

European Union of Medical Specialists (UEMS)

Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC®.

Read more on the Royal College agreement with the European Union of Medical Specialists.

Sponsors

This program has received an educational grant or in-kind support from:

Gold

Merck &Co.
Paladin Labs Inc.

Silver

Gilead Sciences Inc.

Bronze

GlaxoSmithKline
Hoffman-La Roche Ltd.
Pfizer Inc.
Sandoz Canada Inc.
Verity Pharmaceuticals